Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III open-label pediatric study of rVIII-SingleChain in severe hemophilia A
NL-OMON40464Phase 3Active, not recruiting
- Sponsor
- CSL Limited
- Start
- Sep 2014
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of lonoctocog alfa in hemophilia A, sponsored by CSL Limited. Primary endpoint: Efficacy in treatment of major and minor bleeding events. Started Sep 2014; status: active, not recruiting.
02
Drugs
lonoctocog alfa
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NL-OMON40464.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40464.